IDEAYA presents updated Phase 1 data for IDE849 DLL3 ADC at ESMO 2026

IDEAYA Biosciences presented updated Phase 1 results for IDE849 (SHR-4849), a DLL3 TOP1 ADC, at ESMO 2026, showing promising anti-tumor activity and preliminary overall survival results in relapsed small cell lung cancer and neuroendocrine carcinomas.

Detected & updated continuously · Source: Nebula